This practice-oriented handbook surveys current knowledge on the prediction and prevention of adverse drug reactions related to off-target activity of small molecule drugs. It is unique in collating the current approaches into a single source, and includes several highly instructive case studies that may be used as guidelines on how to improve drug development projects. With its large section on ADME-related effects, this is key knowledge for every drug developer.
Roy Vaz is the head of investigative pharmacokinetics at the Bridgewater, NJ (USA) location of Sanofi-Aventis Pharmaceuticals. He received his Ph.D. in Organic Chemistry from the University of Florida, Gainesville (USA), after graduating from the Indian Institute of Technology in Mumbai (India). Prior to his present appointment, he has worked with Bristol-Myers-Squibb and Tripos. He is a specialist on the prediction and modeling of cytochrome-mediated drug metabolism. Thomas Klabunde obtained his PhD in chemistry from the University of Munster (Germany). After a postdoctoral fellowship at the Texas A&M University, he was appointed Assistant Professor at the Institute for Bioscience and Technology in Houston (USA). Later on, he joined the pharmaceutical research of Sanofi-Aventis in Frankfurt (Germany), where he is currently a group leader. His main interest lies with drug design approaches for G protein-coupled receptors, notably in the areas of lead finding and chemogenomics.
PART I: GENERAL ASPECTS Why drugs fail: study on side effects in New Chemical Entities Use of Broad Biological Profiling as a Relevant Descriptor to Describe and Differentiate Compounds: Structure-In Vitro (Pharmacology-ADME)-In Vivo (Safety) Relationships PART II: ANTITARGETS: ION CHANNELS AND GPCRs Pharmacological and regulatory aspects of QT prolongation hERG Channel Physiology and Drug-Binding Structure-Activity Relationships Qsar and Pharmacophores for Drugs Involved in hERG Blockage GPCR Antitarget Modeling: Pharmacophore Models to Avoid GPCR-Mediated Side Effects The Emergence of Serotonin 5-HT2B Receptors as Drug "Antitargets" Computational Modeling of Selective Pharmacophores at the a1-Adrenergic Receptors PART III: ANTITARGETS: CYTOCHROME P450s AND TRANSPORTERS Cytochrome P450s: drug-drug interactions Site of Metabolism Predictions: Facts and Experiences Irreversible Cytochrome P450 Inhibition: Common Sub-Structures and Implications for Drug Development MetaSite: Understanding CYP Antitarget Modeling for Early Toxicity Detection Orphan Nuclear Receptor PXR-Mediated Gene Regulation in Drug Metabolism and Endobiotic Homeostasis Ligand Features Essential for Cytochrome P450 Induction Transporters and Drugs - An Overview Computational Models for P-Glycoprotein Substrates and Inhibitors PART IV: CASE STUDIES OF DRUG OPTIMIZATION AGAINST ANTITARGETS Selective Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes: The Discovery of JANUVIA (Sitagliptin) Strategy and Tactics for hERG Optimizations Structure-Based In Silico Driven Optimization: Discovery of the Selective 5-HT1A Agonist PRX-00023
Number Of Pages:
- ID: 9783527318216
- Saver Delivery: Yes
- 1st Class Delivery: Yes
- Courier Delivery: Yes
- Store Delivery: Yes
Prices are for internet purchases only. Prices and availability in WHSmith Stores may vary significantly
© Copyright 2013 - 2016 WHSmith and its suppliers.
WHSmith High Street Limited Greenbridge Road, Swindon, Wiltshire, United Kingdom, SN3 3LD, VAT GB238 5548 36